These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11056081)

  • 1. Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones.
    Hargreaves RH; Hartley JA; Butler J
    Front Biosci; 2000 Nov; 5():E172-80. PubMed ID: 11056081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications of quinone-containing alkylating agents.
    Begleiter A
    Front Biosci; 2000 Nov; 5():E153-71. PubMed ID: 11056078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of pyrrolo[1,2-alpha]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation.
    Skibo EB; Gordon S; Bess L; Boruah R; Heileman MJ
    J Med Chem; 1997 Apr; 40(9):1327-39. PubMed ID: 9135030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-linking and sequence specific alkylation of DNA BY aziridinylquinones. 1. Quinone methides.
    Mayalarp SP; Hargreaves RH; Butler J; O'Hare CC; Hartley JA
    J Med Chem; 1996 Jan; 39(2):531-7. PubMed ID: 8558523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-linking and sequence specific alkylation of DNA by aziridinyl quinones. 2. Structure requirements for sequence selectivity.
    Hargreaves RH; Mayalarp SP; Butler J; McAdam SR; O'Hare CC; Hartley JA
    J Med Chem; 1997 Jan; 40(3):357-61. PubMed ID: 9022802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-linking and sequence-specific alkylation of DNA by aziridinylquinones. 3. Effects of alkyl substituents.
    Hargreaves RH; O'Hare CC; Hartley JA; Ross D; Butler J
    J Med Chem; 1999 Jun; 42(12):2245-50. PubMed ID: 10377230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity.
    Skibo EB; Xing C; Dorr RT
    J Med Chem; 2001 Oct; 44(22):3545-62. PubMed ID: 11606119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.
    Walton MI; Smith PJ; Workman P
    Cancer Commun; 1991 Jul; 3(7):199-206. PubMed ID: 1714284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemistry and DNA alkylation reactions of aziridinyl quinones: development of an efficient alkylating agent of the phosphate backbone.
    Skibo EB; Xing C
    Biochemistry; 1998 Oct; 37(43):15199-213. PubMed ID: 9790684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships.
    Phillips RM; Naylor MA; Jaffar M; Doughty SW; Everett SA; Breen AG; Choudry GA; Stratford IJ
    J Med Chem; 1999 Oct; 42(20):4071-80. PubMed ID: 10514277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
    Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
    J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?
    Robertson N; Stratford IJ; Houlbrook S; Carmichael J; Adams GE
    Biochem Pharmacol; 1992 Aug; 44(3):409-12. PubMed ID: 1510692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The autoxidation of the reduced forms of EO9.
    Butler J; Spanswick VJ; Cummings J
    Free Radic Res; 1996 Aug; 25(2):141-8. PubMed ID: 8885332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the cytotoxic and physical properties of aziridinyl quinone derivatives based on the pyrrolo[1,2-a]benzimidazole and pyrrolo[1,2-a]indole ring systems.
    Boruah RC; Skibo EB
    J Med Chem; 1994 May; 37(11):1625-31. PubMed ID: 8201596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
    Plumb JA; Workman P
    Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sigmatropic reactions of the aziridinyl semiquinone species. Why aziridinyl benzoquinones are metabolically more stable than aziridinyl indoloquinones.
    Xing C; Skibo EB
    Biochemistry; 2000 Sep; 39(35):10770-80. PubMed ID: 10978162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development.
    Beall HD; Winski SI
    Front Biosci; 2000 Jul; 5():D639-48. PubMed ID: 10877993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of the aziridinyl substituent of benzimidazoles and benzimidazolequinones on toxicity towards normal and Fanconi anaemia cells.
    Fahey K; O'Donovan L; Carr M; Carty MP; Aldabbagh F
    Eur J Med Chem; 2010 May; 45(5):1873-9. PubMed ID: 20122765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of cancer-specific antitumor agents based on aziridinylcyclopent[b]indoloquinones.
    Xing C; Wu P; Skibo EB; Dorr RT
    J Med Chem; 2000 Feb; 43(3):457-66. PubMed ID: 10669573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
    Bailey SM; Suggett N; Walton MI; Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.